Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2017 pubmed 52 citations

LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2.

Yu. Yangyang Y; Zhang. Yuanyuan Y; Zhang. Yarui Y; Lai. Yihong Y; Chen. Wenwen W; Xiao. Zhangang Z; Zhang. Wei W; Jin. Meiling M; Yu. Bo B

Key Findings

  • LL-37 triggers mast cell degranulation and IL-8 release primarily through the MrgX2 receptor.
  • Silencing MrgX2 dramatically reduces LL-37‑induced mast cell activation.
  • Other receptors (FPRL1, P2X7) have limited impact on IL-8 release and do not affect degranulation.

Practical Outcomes

  • If you’re considering LL-37 as a supplement or therapeutic, expect it may provoke mast cell‑driven inflammation via MrgX2. This suggests caution for people prone to allergic or inflammatory reactions. Targeting or avoiding MrgX2 activation could be a strategy to mitigate unwanted side effects.

Summary

The study shows that the antimicrobial peptide LL-37 makes human mast cells release their stored chemicals and produce new inflammatory signals mainly by binding to a receptor called MrgX2. Turning off MrgX2 stops this reaction, while other receptors play only a minor role.

Abstract

Human LL-37 is an important class of cationic antimicrobial peptide (CAP) that is known to stimulate mast cell activation. While many studies have been conducted on LL-37, to date little is known about the functional receptors for LL-37-induced human mast cell activation, in particular in terms of the release of de novo synthesized mediators. Thus, the aim of the present study is to identify the functional receptors for LL-37-induced human mast cell activation in terms of the degranulation and release of de novo synthesized mediators and investigate the downstream signalling pathways involved in mast cell activation. Overall, our study importantly demonstrates that LL-37-induced human mast cell degranulation and release of de novo synthesized mediators function primarily through the activation of MrgX2. We furthermore show that LL-37-induced human mast cell line LAD2 cells are involved in the degranulation and release of IL-8, and that FPRL1 and P2X7 have only a partial effect on IL-8 release, and no effect on mast cell degranulation triggered by LL-37. Instead, we find that silencing the expression of MrgX2 in human mast cell significantly inhibits the LL-37-induced degranulation and release of IL-8. Overall, this effect is associated with the activation of the G<sub>i</sub> protein, PLC/PKC/Calcium/NFAT, PI3K/Akt and MAPKs signalling pathways.

Study Information

Provider

pubmed

Year

2017

Date

2017-05-23T00:00:00.000Z

DOI

10.1016/j.intimp.2017.05.016

Citations

52

References

33